Arpa-h embody: development of an affordable and exceptionally efficient vector platform for highly specific reprogramming of t cells and b cell
Active Other Transaction Agreement Awarded Last action
- Contract number
- 140D042590017
- Awardee
-
Mucommune LLC UEI NWVPL2L4JMN8
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $6,146,970
Award facts
- Contract value 21% obligated
-
- $6,146,970.00 Current, with exercised options
- $29,440,547.00 Potential, with all options
- Completion date 19% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institutes of Health Department of Health and Human Services
- NAICS code
- Not on record
- Competition
- Competed Program Solicitation
- Pricing
- Other
- Place of performance
- Durham, NC 27707, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $6,146,970 |
About this award
Mucommune LLC, a Durham, North Carolina-based biopharmaceutical company, has been awarded a $29.4 million Other Transaction Agreement by the National Institutes of Health under the ARPA-H EMBODY program. The contract, awarded September 3, 2025, with an ultimate completion date of September 2, 2031, focuses on developing an affordable and exceptionally efficient vector platform for highly specific reprogramming of T cells and B cells in situ. This award represents a significant commitment to advancing cellular immunotherapy technologies, building upon Mucommune's existing expertise in CAR-T cell development and targeted biological interventions.
The Other Transaction Agreement vehicle allows for flexible contracting mechanisms outside traditional federal procurement rules, enabling accelerated development of innovative biotechnologies. As a small business, Mucommune brings specialized research capabilities in cellular engineering and immunotherapy to this high-impact initiative, which aligns with the company's demonstrated track record in developing advanced medical solutions across oncology and infectious disease prevention. The EMBODY program's focus on in situ cell reprogramming represents a frontier approach to immunotherapy, potentially offering more efficient and accessible treatment options compared to ex vivo manufacturing processes.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| University Of North Carolina At Chapel Hill | $3,108,821 |
Quick answers
Who was awarded contract 140D042590017?
140D042590017 was awarded to Mucommune LLC by Interior Business Center (Office of Policy Management and Budget) on September 3, 2025.
How much is contract 140D042590017 worth?
The government has obligated $6,146,970 on 140D042590017. Its potential value, with all options, is $29,440,547.
Which agency awarded contract 140D042590017?
Interior Business Center (Office of Policy Management and Budget) awarded 140D042590017, with funding from National Institutes of Health (Department of Health and Human Services).
Was contract 140D042590017 competed?
The extent of competition for 140D042590017 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award